Schorno Dean L
SEC CIK 1509688 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| RIGL | RIGEL PHARMACEUTICALS INC | EVP, CFO | 83.0K | — | $103.9K | 15 | 2022-01-24 | 2026-09-02 |
Most active insiders at RIGL, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Ali-Jackson Kamil | Dir | — | $160.4K |
| 2 | MOOS WALTER H | Dir | — | $145.4K |
| 3 | Rojkjaer Lisa | EVP, Chief Medical Off | — | — |
| 4 | Santos David A | EVP, Chief Commercial Off | — | — |
| 5 | HANNAH ALISON L. | EVP, Chief Medical Off | — | — |
| 6 | Furey Raymond J. | EVP, GC, CCO, Corp Sec | — | — |
| 7 | Schorno Dean L | EVP, CFO | — | — |
| 8 | Frohlich Mark W | Dir | — | — |
| 9 | Wasman Jane | Dir | — | — |
| 10 | LAPOINTE ANTHONY GREGG | Dir | — | — |
Transactions 15
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-09-03 19:02 | 2026-09-01 | RIGL | RIGEL PHARMACEUTICALS INC | Schorno Dean L | EVP, CFO | F - Tax | $47.50 | -928 | 78.4K | -1% | -$44.1K |
| DM | 2026-09-03 19:02 | 2026-09-02 | RIGL | RIGEL PHARMACEUTICALS INC | Schorno Dean L | EVP, CFO | M - OptEx | $21.72 | +4,600 | 83.0K | +6% | +$99.9K |
| DM | 2026-06-03 18:03 | 2026-06-01 | RIGL | RIGEL PHARMACEUTICALS INC | Schorno Dean L | EVP, CFO | M - OptEx | $14.83 | +3,381 | 79.7K | +4% | +$50.1K |
| D | 2026-06-03 18:03 | 2026-06-01 | RIGL | RIGEL PHARMACEUTICALS INC | Schorno Dean L | EVP, CFO | F - Tax | $29.86 | -928 | 78.8K | -1% | -$27.7K |
| 2026-02-19 | 2026-02-17 | RIGL | RIGEL PHARMACEUTICALS INC | Schorno Dean L | EVP, CFO | A - Grant | $0.00 | +20.6K | 76.3K | +37% | $0 | |
| 2026-02-12 | 2026-02-10 | RIGL | RIGEL PHARMACEUTICALS INC | Schorno Dean L | EVP, CFO | F - Tax | $34.62 | -3,546 | 55.7K | -6% | -$122.8K | |
| 2026-02-04 | 2026-02-02 | RIGL | RIGEL PHARMACEUTICALS INC | Schorno Dean L | EVP, CFO | F - Tax | $36.01 | -5,488 | 59.2K | -8% | -$197.6K | |
| DM | 2025-12-29 | 2025-12-22 | RIGL | RIGEL PHARMACEUTICALS INC | Schorno Dean L | EVP, CFO | M - OptEx | $21.51 | +6,500 | 59.7K | +12% | +$139.8K |
| M | 2025-02-06 | 2025-02-04+ | RIGL | RIGEL PHARMACEUTICALS INC | Schorno Dean L | EVP, CFO | S - Sale | $21.38 | -3,770 | 57.2K | -6% | -$80.6K |
| D | 2025-01-31 | 2025-01-29 | RIGL | RIGEL PHARMACEUTICALS INC | Schorno Dean L | EVP, CFO | A - Grant | $0.00 | +19.7K | 61.0K | +48% | $0 |
| M | 2024-02-06 | 2024-02-02+ | RIGL | RIGEL PHARMACEUTICALS INC | Schorno Dean L | EVP, CFO | S - Sale | $1.14 | -12.6K | 409.9K | -3% | -$14.3K |
| D | 2024-01-25 | 2024-01-23 | RIGL | RIGEL PHARMACEUTICALS INC | Schorno Dean L | EVP, CFO | A - Grant | $0.00 | +209.0K | 415.5K | +101% | $0 |
| 2023-02-06 | 2023-02-02 | RIGL | RIGEL PHARMACEUTICALS INC | Schorno Dean L | EVP, CFO | S - Sale | $1.66 | -5,389 | 196.5K | -3% | -$8,946 | |
| D | 2023-01-30 | 2023-01-26 | RIGL | RIGEL PHARMACEUTICALS INC | Schorno Dean L | EVP, CFO | A - Grant | $0.00 | +63.0K | 201.9K | +45% | $0 |
| D | 2022-01-26 | 2022-01-24 | RIGL | RIGEL PHARMACEUTICALS INC | Schorno Dean L | EVP, CFO | A - Grant | $0.00 | +50.0K | 128.9K | +63% | $0 |
Purchase Sale Sale after option exercise All abbreviations